GlassScriptPhysician profile
Robert Elliott Gray
NPI 1285392464
$9,333.75
in general payments reported to CMS, 2019-2025
24 companies · $4,829 in 2025
The $4,829 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,586 · 2024: $2,918 · 2025: $4,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,145 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,145.11 |
| Education | $188.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,294.00 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,140.15 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,041.99 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $826.32 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $716.83 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $654.96 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $561.29 | 2023-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $470.85 | 2023-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Bausch Health US, LLC | $383.75 | 2023-2025 | Wellbutrin, Aplenzin |
| Lundbeck LLC | $367.11 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $284.76 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $265.39 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $252.28 | 2024-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $235.83 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $230.75 | 2023-2025 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $213.23 | 2024-2025 | Brixadi |
| Noven Therapeutics, LLC | $96.70 | 2023-2025 | Secuado, Xelstrym |
| Uswm, LLC | $89.30 | 2023-2024 | Lucemyra, Zimhi |
| Idorsia Pharmaceuticals US INC | $79.70 | 2023 | Quviviq |
| Tris Pharma INC | $46.26 | 2023-2025 | Dyanavel Xr |
| Luye Pharma (USA) LTD. | $26.73 | 2025 | Erzofri Extended-Release |
| Collegium Pharmaceutical, INC. | $22.18 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $16.99 | 2023 | Belsomra |
| Corium, LLC | $16.40 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.